SCHEMBL1963425

SCHEMBL1963425

CC(C)=C[CH]CC=C(C)C

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23163332 0.77 KMT2A (0.64) ALDH1A1KMT2A
SCHEMBL6683011 0.77 KMT2A (0.64) ALDH1A1KMT2A
SCHEMBL1305942 0.75
SCHEMBL704379 0.75 ALDH1A1 (0.59) ALDH1A1KMT2A
SCHEMBL6131066 0.73
SCHEMBL6907916 0.73
SCHEMBL6924137 0.71 KMT2A (0.64) ALDH1A1KMT2A
SCHEMBL3492594 0.69 KMT2A (0.36) ALDH1A1KMT2A
SCHEMBL158028 0.68 KMT2A (0.60) ALDH1A1KMT2A
SCHEMBL1305503 0.67 NR1I2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107847606-A Conjugates comprising self-degrading groups and methods relating thereto 乐高化学生物科学股份有限公司 2018-03-27 CN disclosed
EP-2908634-A1 PRENYLATED CHALCONE FORMULATION FOR THE TREATMENT OF BEES Bioactive-tech Sp. z z.o. (PL) 2015-08-26 EP disclosed
US-9045524-B2 Selective caspase inhibitors and uses thereof NOVAGENESIS FOUNDATION (CH) 2015-06-02 US disclosed
WO-2014060803-A1 PRENYLATED CHALCONE FORMULATION FOR THE TREATMENT OF BEES BIOACTIVE-TECH SP. Z O.O. (PL) 2014-04-24 WO disclosed
US-8563599-B2 Methods for synthesizing glycinols, glyceollins I and II, compositions of selected intermediates, and therapeutic uses thereof THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2013-10-22 US disclosed
US-8450560-B2 Gene cluster of prenyl transferase from Hevea brasiliensis BRIDGESTONE CORPORATION (JP) 2013-05-28 US disclosed
US-20120157394-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF NEW WORLD LABORATORIES, INC. (CA) 2012-06-21 US disclosed
US-20110144195-A1 METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF XAVIER UNIVERSITY OF LOUISIANA 2011-06-16 US disclosed
US-20100186111-A1 GENE CLUSTER OF PRENYL TRANSFERASE FROM HEVEA BRASILIENSIS BRIDGESTONE CORPORATION (JP) 2010-07-22 US disclosed
US-7692066-B2 Gene cluster of prenyl transferase from Hevea brasiliensis BRIDGESTONE CORPORATION (JP) 2010-04-06 US disclosed
WO-2008003774-A1 METHOD FOR PRODUCING ENANTIOPURE FLAVANONES Technische Universität Dresden (DE) 2008-01-10 WO disclosed
US-20070067866-A1 Gene cluster of prenyl transferase from Hevea brasiliensis BRIDGESTONE CORPORATION 2007-03-22 US disclosed
EP-0381205-A2 Process for the polymerisation of polar compounds WACKER-CHEMIE GMBH (DE) 1990-08-08 EP disclosed
US-4087468-A MAGNESIUM WITH ZINC, CADMIUM, MERCURY OR INDIUM HALIDE, AN ALIPHATIC HALIDE PROMOTER AND AN ETHER DILUENT PHILLIPS PETROLEUM COMPANY (US) 1978-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144195-A1 METHODS FOR SYNTHESIZING GLYCINOLS, GLYCEOLLINS I AND II, COMPOSITIONS OF SELECTED INTERMEDIATES, AND THERAPEUTIC USES THEREOF GPER1, ESR2, GNE ALDH1A1 3569/4885KMT2A 3625/4885
US-20120157394-A1 SELECTIVE CASPASE INHIBITORS AND USES THEREOF CASP1, VIP, CASP5 ALDH1A1 4093/4885KMT2A 3517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.